Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
National Institutes of Health (NIH) sent this bulletin at 05/26/2020 05:30 PM EDTHaving trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
05/26/2020 04:00 PM EDT
Dose-adjusted EPOCH-R is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting.